GYRE Gyre Therapeutics, Inc.

NASDAQ
$4.52

Gyre Therapeutics, Inc. (GYRE) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.9% since its last earnings release on November 5, 2026.

Gyre Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 4:07 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.10)
Rev est $29.64M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Gyre Therapeutics, Inc.

Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.